Drug intelligence / Profile preview

valsartan + amlodipine + chlorthalidone

Development stage
Unknown
Lead developer
AJU Pharm
Modality
Small Molecules
Administration
Oral
01

Overview

This drug is a **fixed-dose combination** of three antihypertensive agents: valsartan, amlodipine, and chlorthalidone. - **Valsartan** is an angiotensin II receptor blocker (ARB) that inhibits the action of angiotensin II on the AT1 receptor, leading to vasodilation and reduced blood pressure. - **Amlodipine** is a dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle, causing arterial vasodilation and reduction in blood pressure. - **Chlorthalidone** is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule of the nephron, promoting diuresis and reducing blood volume and blood pressure. This triple combination is typically used for the treatment of **hypertension**, especially in patients who require multiple antihypertensive agents to achieve target blood pressure levels. Most commonly, fixed combinations available in the market substitute chlorthalidone with hydrochlorothiazide in similar triple therapies, but the pharmacologic effects are considered clinically similar.

Other names
valsartan + amlodipine + chlorthalidone
02

Targets

SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)LTCC (Voltage-gated calcium channel (L-type))AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on valsartan + amlodipine + chlorthalidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on valsartan + amlodipine + chlorthalidone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call